MCO formularies adding new products
More than 20 new drugs were added to the Fall 2000 edition of Newtown, PA-based Scott-Levin's Managed Care Formulary Drug Audit. Betapace AF™ (sotalol HCl), a cardiovascular therapy manufactured by Berlex Laboratories Inc., Montville, NJ, was the new product with the highest level of formulary acceptance, according to the audit.
More than 20 new drugs were added to the Fall 2000 edition of Newtown, PA-based Scott-Levin's Managed Care Formulary Drug Audit. Betapace AF⢠(sotalol HCl), a cardiovascular therapy manufactured by Berlex Laboratories Inc., Montville, NJ, was the new product with the highest level of formulary acceptance, according to the audit.
Betapace AF, indicated for treatment of atrial fibrillation or flutter in patients without congestive heart failure, was on formulary at 54% of the managed care plans surveyed.
While Betapace AF appeared on the largest number of formularies, the new brand that was available to the largest number of drug-plan-eligible members was New York-based Bristol-Myers Squibb Co.'s Glucovance® (glyburide and metformin HCl tablets), an oral treatment for type II diabetes.
The third tier
According to Scott-Levin, 70% of panelists who had a portion of their membership enrolled in a three-tier benefit design made approved drugs not yet reviewed by the managed care plan available to members at the third-tier co-pay level.
Of the new products, Glucovance was among the least likely to appear in the more expensive third tier. Thirty-one percent of the plans surveyed that offered a three-tier benefit to their members placed Glucovance in the third tier. The drug was offered at the highest co-pay to only 17% of members enrolled in three-tier benefit plans. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
